Effects of Adenosine Receptor Antagonists on the In Vivo LPS-Induced Inflammation Model of Parkinson's Disease

Author： Gołembiowska Krystyna  

Publisher： Springer Publishing Company

ISSN： 1029-8428

Source： Neurotoxicity Research, Vol.24, Iss.1, 2013-07, pp. : 29-40

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

- and -Opioid Receptor Antagonists Reduce Levodopa-Induced Dyskinesia in the MPTP-Lesioned Primate Model of Parkinson's Disease

By Henry B.   Fox S.H.   Crossman A.R.   Brotchie J.M.  

Experimental Neurology, Vol. 171, Iss. 1, 2001-09 ,pp. : 139-146

Elsevier

Access to resources Recommend Favorite

Adenosine A 2A antagonists: potential preventive and palliative treatment for Parkinson's disease

By Morelli M.  

Experimental Neurology, Vol. 184, Iss. 1, 2003-11 ,pp. : 20-23

Elsevier

Access to resources Recommend Favorite

Parkinson's disease: PET studies, neural stem cells and an adenosine receptor antagonist

By Strupp Michael  

Journal of Neurology, Vol. 255, Iss. 4, 2008-04 ,pp. : 616-618

Springer Publishing Company

Access to resources Recommend Favorite

Preladenant: an adenosine A2A receptor antagonist for Parkinson’s disease

By Zúñiga-Ramírez Carlos   Micheli Federico  

Future Neurology, Vol. 8, Iss. 6, 2013-11 ,pp. : 639-648

Future Medicine

Access to resources Recommend Favorite

Protective effect of adenosine in rat model of Parkinson's disease: neurobehavioral and neurochemical evidences

By Zafar K.S.   Siddiqui A.   Sayeed I.   Ahmad M.   Saleem S.   Islam F.  

Journal of Chemical Neuroanatomy, Vol. 26, Iss. 2, 2003-10 ,pp. : 143-151

Elsevier

Access to resources Recommend Favorite